J&J Experimental Prostate Cancer Drug Shrinks Tumors in Early-Stage Trial

Johnson & Johnson said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial. The company obtained access to the drug through its $3.05 billion deal to buy Halda Therapeutics last year.